Safety and effectiveness of rivaroxaban in anticoagulation therapy for elderly patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011918

Enrollment

Unknown

Registered

2017-07-09

Start date

2017-07-14

Completion date

Unknown

Last updated

2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thrombosis

Interventions

rivaroxaban group:rivaroxaban

control group:other anticoagulation therapy

Eligibility

Sex/Gender

All

Age

75 Years to 150 Years

Inclusion criteria

Inclusion criteria: 1. aged 75 and older; 2. patients needed anticoagulation therapy in Shanghai Xinhua Hospital, including patients with atrial fibrillation, pulmonary embolism, deep vein thrombosis, high risk of venous thrombosis; 3. voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with contraindication of anticoagulation; 2. participation in other clinical study.

Design outcomes

Primary

Measure	Time frame
Major Bleeding;	—

Secondary

Measure	Time frame
Clinically Relevant Non-major Bleeding;thromboembolic event;death event;	—

Countries

China

Contacts

Public ContactZhen Li

Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

zhenli1991@163.com+86 15216635171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026